BioAsset

Insights / All articles

Research

Lilly Neuroscience

By Neev Mohindroo, Research Analyst at BioAsset · 5 slides

Eli Lilly closed one of its biggest weeks on record. Three major strategic moves, an acquisition, a collaboration and a European regulatory win, sent shares to a new all-time high of $1,215.76 on June 26, up 7.13% in a single session.

Lilly is not just winning in one category. It is simultaneously dominating obesity, diabetes, oncology and Alzheimer’s, and now expanding further into neuroscience by targeting sleep disorders and neurodegeneration. No other pharmaceutical company is running this many growth tracks at such a high scale. Right now, Eli Lilly stands alone in the health sector.

A snapshot of its market position by therapeutic area shows roughly 60% global share in obesity (GLP-1), 53%+ ex-US share in diabetes (GLP-1), neuroscience revenue growing 160% year over year, an FDA-approved Alzheimer’s drug in Kisunla, and EU approval imminent in oncology (CLL). Its therapeutic footprint as of June 2026 pairs the existing franchises, Mounjaro in diabetes at $8.7B in Q1, obesity GLP-1s, Kisunla in Alzheimer’s and Jaypirca in oncology, with three areas added this week: sleep and narcolepsy, neurodegeneration and pain. Lilly’s market capitalization stands at $1.14T.

The two deals

The first was the full acquisition of Centessa Pharmaceuticals, announced June 24. Centessa is a clinical-stage UK pharma company founded in 2021 that developed orexin receptor 2 (OR2) agonists, a new drug class targeting the brain’s wake-promoting system, aimed at narcolepsy and other sleep-wake disorders. The target market is around $3B+ globally. The deal is worth up to $7.8B, with $6.3B upfront.

The second was a research collaboration with BioArctic AB, announced June 22, centered on neurodegeneration. BioArctic is a Swedish biotech listed on Nasdaq Stockholm. Its proprietary BrainTransporter platform enables drugs to cross the blood-brain barrier, and the company previously developed lecanemab for Alzheimer’s, now licensed to Eisai. Lilly pays $30M upfront with more than $770M in milestones, for a total potential value above $800M. The milestone structure breaks down into roughly $200M in development milestones, $250M in regulatory milestones and $320M in commercial milestones, plus tiered mid-single-digit percentage royalties on all global product sales.

What each side gets

For Lilly, the stock hit a new all-time high of $1,215.76 on June 26, up from a 52-week low of $623.78, nearly doubling in a year. Two neuroscience deals in a single week signal an intent to build a durable CNS franchise. The Centessa acquisition hands Lilly a clinical-stage OR2 program it can develop on its own, accelerating the path to market for a promising drug. The BioArctic deal gives Lilly a platform rather than a single drug, one that could unlock a whole new class of CNS therapeutics that previously could not reach the brain. Lilly also has a Medicare patient expansion ahead, going from 3.5M to 23.5M patients covered, a 6.7x increase.

For Centessa, the acquisition removes all commercialization risk and gives the OR2 agonist best-in-class manufacturing, infrastructure and commercial reach. With Lilly behind it, the drug can reach approval faster, and Centessa shareholders received a full exit at what was likely a significant premium.

For BioArctic, the $30M upfront provides immediate capital, and the $770M milestone structure means the company participates directly in the upside if the program succeeds. Having Lilly’s name behind BrainTransporter also gives the platform instant credibility with other potential partners.

Is LLY worth investing in?

Lilly trades at 43x P/E, expensive by any pharma standard. But this is not a typical pharma company anymore. Lilly is dominating the largest new drug market in a generation in GLP-1s, building out a neuroscience platform, and is about to see its revenue model benefit from the biggest Medicare coverage expansion in obesity drug history. The stock carries a premium, and it still might be underpriced.

Revenue backs that up: $12.73B in Q1 2025, $19.3B in Q4 2025 and $19.8B in Q1 2026, up 56% year over year. Of 31 analyst ratings as of June 2026, six are strong buy (19%), 18 are buy (58%) and five are hold (16%), with an average price target of $1,218.72.

Bottom line: lean bullish, and watch their news closely.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.